|Licensing opportunity DI 05/12
Recombinant Plasmodium Falciparum merozoite surface proteins 4 and 5 and their use
Inventors: Shirley LONGACRE et al.
Description of invention:
This invention describes two antigens which are P. falciparum merozoite surface proteins 4 and 5 (PfMSP4; PfMSP5). These antigens have been produced in soluble form in the baculovirus / insect expression system, and extensively purified in mg amounts using metallo-affinity chromatography. Some of the expressed proteins, which were designed to include only regions with minimal polymorphism, are highly immunogenic in rabbits and produced antibodies react specifically with parasite extracts. Sera from endemic malaria-exposed donors react with the recombinant PfMSP4 and PfMSP5 antigens, and the antibody response is statistically associated with protection from clinical disease. These data indicate that these antigens deserve further development as malaria blood stage vaccine candidates.
Malaria blood stage vaccine.
US provisional patent application filed on November 23rd, 2005 (US 60 / 739,973)
PCT patent application filed on November 23rd, 2006 (PCT / IB2006 / 003967)
US regular patent application filed on November 23rd, 2006 (US 11 / 603,793)
Gene polymorphism of Plasmodium falciparum merozoite surface proteins 4 and 5.
Polson, H., Conway, D., Fandeur, T., Mercereau-Puijalon, O., Longacre, S.,
Mol Biochem Parasitol. 2005 Jul ;142(1) :110-5.
Contact : Vincent Charpentier, Business Development Manager - Office of Technology Transfer
Institut Pasteur - 28 Rue du Docteur Roux - 75724 Paris Cedex 15 FRANCE
Tel : 33.1.45 68 81 87 - Fax : 126.96.36.199.37.32 - email : firstname.lastname@example.org